| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | | | |
| | |
|
| |
|
The use of gas as a contrast medium has significant potential to avoid limitations of conventional contrast agents. Gases can transit smaller vascular conduits and can be injected through smaller and less traumatic access systems than liquids. Highly soluble gases (such as CO2) can be imaged as a bolus. Blood is displaced by the gas, with the result of negative image contrast.
Because gases are compressible, standard liquid injectors
cannot be used. The design for a gasinjector should have the option for individual adaptation of blood flow rate, vessel diameter, pulse pressure, and heart rate. | | | | | Further Reading: | News & More:
|
|
| | | |
|
| |
| Vasovist™ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovist™ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovist™ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVAR™), to Lantheus Medical Imaging, Inc..
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m 2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.
See also MRI Safety.
Drug Information and Specification NAME OF COMPOUND Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325 T1, predominantly positive enhancement 20-45 mmol-1sec-1, Bo=0,47T PHARMACOKINETIC Intravascular, short elimination half life CONCENTRATION 244 mg/mL, 0.25mmol/mL DOSAGE 0.12 mL/kg, 0.03 mmol/kg DEVELOPMENT STAGE approved DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information TERRITORY TRADE NAME DEVELOPMENT STAGE DISTRIBUTOR North America, Australia for sale | | | | • View the DATABASE results for 'Vasovist™' (7).
| | | | Further Reading: | Basics:
|
|
| | | | | | |
|
| |
| A vector is a quantity characterized by a magnitude (in mathematics a number, in physics a number times a unit) and a direction (and a point of application), often represented graphically by an arrow. The length of the line segment represents the magnitude, and its orientation in space represents its direction. Vector quantities can be added to or subtracted from one another. Used in MRI to describe forces, e.g. magnetic moment, spin, magnetization etc. | | | | • View the DATABASE results for 'Vector' (38).
| | | | Further Reading: | Basics:
|
|
| | | | | |
|
| |
| | | | | • View the DATABASE results for 'Velocity Compensation' (2).
| | | | Further Reading: | Basics:
|
|
| | | | | | |
| | |
|
| |
| Look Ups |
| |